Is Tobacco Use Associated With Risk of Recurrence and Mortality Among People With TB?: A Systematic Review and Meta-Analysis.

TB meta-analysis risk of mortality risk of recurrence smoking systematic review tobacco

Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
29 Aug 2023
Historique:
received: 24 01 2023
revised: 20 06 2023
accepted: 23 08 2023
pubmed: 1 9 2023
medline: 1 9 2023
entrez: 31 8 2023
Statut: aheadofprint

Résumé

Associations between tobacco use and poor TB treatment outcomes are well documented. However, for important outcomes such as TB recurrence or relapse and mortality during treatment, as well as for associations with smokeless tobacco (ST), the evidence is not summarized systematically. Is tobacco use associated with risk of poor treatment outcomes among people with TB? The MEDLINE, Embase, and Cumulative Index of Nursing and Allied Health Literature databases were searched on November 22, 2021. Epidemiologic studies reporting associations between tobacco use and at least one TB treatment outcome were eligible. Independent double-screening, extractions, and quality assessments were undertaken. Random effects meta-analyses were conducted for the two primary review outcomes (TB recurrence or relapse and mortality during treatment), and heterogeneity was explored using subgroups. Other outcomes were synthesized narratively. Our searches identified 1,249 records, of which 28 were included in the meta-analyses. Based on 15 studies, higher risk of TB recurrence or relapse was found with ever using tobacco vs never using tobacco (risk ratio [RR], 1.78; 95% CI, 1.31-2.43; I Tobacco use significantly increases the risk of TB recurrence or relapse and mortality during treatment among people with TB, highlighting the need to address tobacco use to improve TB outcomes. PROSPERO; No.: CRD42017060821; URL: https://www.crd.york.ac.uk/prospero/.

Sections du résumé

BACKGROUND BACKGROUND
Associations between tobacco use and poor TB treatment outcomes are well documented. However, for important outcomes such as TB recurrence or relapse and mortality during treatment, as well as for associations with smokeless tobacco (ST), the evidence is not summarized systematically.
RESEARCH QUESTION OBJECTIVE
Is tobacco use associated with risk of poor treatment outcomes among people with TB?
STUDY DESIGN AND METHODS METHODS
The MEDLINE, Embase, and Cumulative Index of Nursing and Allied Health Literature databases were searched on November 22, 2021. Epidemiologic studies reporting associations between tobacco use and at least one TB treatment outcome were eligible. Independent double-screening, extractions, and quality assessments were undertaken. Random effects meta-analyses were conducted for the two primary review outcomes (TB recurrence or relapse and mortality during treatment), and heterogeneity was explored using subgroups. Other outcomes were synthesized narratively.
RESULTS RESULTS
Our searches identified 1,249 records, of which 28 were included in the meta-analyses. Based on 15 studies, higher risk of TB recurrence or relapse was found with ever using tobacco vs never using tobacco (risk ratio [RR], 1.78; 95% CI, 1.31-2.43; I
INTERPRETATION CONCLUSIONS
Tobacco use significantly increases the risk of TB recurrence or relapse and mortality during treatment among people with TB, highlighting the need to address tobacco use to improve TB outcomes.
TRIAL REGISTRY BACKGROUND
PROSPERO; No.: CRD42017060821; URL: https://www.crd.york.ac.uk/prospero/.

Identifiants

pubmed: 37652295
pii: S0012-3692(23)05372-2
doi: 10.1016/j.chest.2023.08.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Financial/Nonfinancial Disclosures None declared.

Auteurs

Aishwarya Lakshmi Vidyasagaran (AL)

Department of Health Sciences, University of York, York, England.

Anne Readshaw (A)

Department of Health Sciences, University of York, York, England; Yorkshire and North Lincolnshire Area Team, Natural England.

Melanie Boeckmann (M)

Department of Global Health, Institute of Public Health and Nursing Research (IPP), University of Bremen, Bremen, Germany.

Alexander Jarde (A)

Université de Paris, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, and Cochrane France, Paris, France.

Faraz Siddiqui (F)

Department of Health Sciences, University of York, York, England.

Anna-Marie Marshall (AM)

Department of Health Sciences, University of York, York, England; Research Fellow in Public Health and lecturer in Public Health and Psychology, Helen McArdle Nursing and Care Research Institute, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, England.

Janita Akram (J)

Hull York Medical School, University of York, York, England.

Jonathan E Golub (JE)

Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, MD.

Kamran Siddiqi (K)

Department of Health Sciences, University of York, York, England; Hull York Medical School, University of York, York, England.

Omara Dogar (O)

Department of Health Sciences, University of York, York, England; Usher Institute, The University of Edinburgh, Edinburgh, Scotland. Electronic address: omara.dogar@york.ac.uk.

Classifications MeSH